Clinical Trials Directory

Trials / Completed

CompletedNCT04882449

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events

Surveillance and Alert-based Multiparameter Monitoring to Reduce Worsening Heart Failure Events - SCALE-HF1

Status
Completed
Phase
Study type
Observational
Enrollment
329 (actual)
Sponsor
Bodyport Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The main goal of this study is to use data from the Bodyport Cardiac Scale to help detect of worsening heart failure (HF) early.

Detailed description

The overarching goal of this prospective, multicenter study is to utilize data from the Bodyport Cardiac Scale to develop an index that allows for the early detection of worsening heart failure (HF). The Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF. The SCALE-HF program will consist of multiple phases. For SCALE-HF 1, patients will be prospectively enrolled and utilize the Bodyport Cardiac Scale on a daily basis. Patients and clinicians will be blinded to the results other than data readily available from other devices such as body weight. There will be no attempt to influence clinical practice. Patients will be followed remotely for suspected clinical events.

Conditions

Interventions

TypeNameDescription
DEVICEBodyport Cardiac ScaleThe Bodyport Cardiac Scale is capable of measuring key HF parameters of congestion and cardiac perfusion on a regular basis in a patient's home. These data will be combined into a composite index that may be used to identify patients at increased risk for decompensation, inform the reason for their decline, and offer the possibility to remotely optimize therapy to prevent further worsening HF.

Timeline

Start date
2021-07-08
Primary completion
2023-04-30
Completion
2023-07-31
First posted
2021-05-12
Last updated
2025-02-10
Results posted
2025-02-10

Locations

8 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT04882449. Inclusion in this directory is not an endorsement.